Evogen, Inc.

Evogen, Inc. is a biotechnology company specializing in advanced solutions for Neurology Proteomics and Genomics, focusing on precision medicine and pathogen detection technologies. Founded in 2002 in Lower Gwynedd, US, Evogen, Inc. focuses on precision medicine and pathogen detection technologies.

The company has undergone strategic changes to enhance its offerings and was previously involved in various funding rounds, most recently a Series B round where it raised USD 0. 850 mn from L Catterton. The current company valuation stands at USD 2. 337 mn.

Evogen specializes in advanced solutions for Neurology Proteomics and Genomics, focusing on precision medicine and pathogen detection technologies. The company's core offerings include EvoScore, which delivers objective measurements for the rapid diagnosis of neurological diseases, and HyBeacons, an innovative High Definition PCR (HD PCR™) technology designed for accurate pathogen detection across a range of applications, including infectious diseases, food safety, and biodefense. Additionally, Evogen's SpinCon portable air sampler is engineered for the efficient collection of bioaerosols and pathogens, addressing critical health threats. These products are utilized by healthcare providers, research institutions, and various industries globally, with significant market penetration in North America, Europe, and Asia.

Evogen's commitment to addressing unmet medical needs and enhancing treatment outcomes positions its solutions as essential tools in modern healthcare. Evogen's revenue model is primarily driven by B2B transactions, engaging directly with healthcare providers, research labs, and governmental agencies. The company structures its transactions through strategic partnerships, contracts for product supply, and potentially licensing agreements for its technologies, such as HyBeacons and EvoScore. These offerings are sold through various pricing plans tailored to the specific needs of clients, with options ranging from one-time purchases to subscription-based models for ongoing access to diagnostic tools and updates.

Thus, Evogen generates revenue through both the sale of individual products and long-term collaborations aimed at advancing precision medicine and enhancing public health safety. Evogen plans to expand its market presence by developing new products aimed at improving diagnostic capabilities in neurology and infectious disease detection. The company is targeting additional markets in Europe and Asia by 2025 to enhance its global footprint. The recent funding from the Series B round will be utilized to support the development of these new product lines and to finance the expansion into new geographic regions.